Gemifloxacin once daily for 5 days versus 7 days for the treatment of community-acquired pneumonia: a randomized, multicentre, double-blind study
The DOI matches its Crossref record.
Abstract
Short-course therapy has been advocated for the treatment of community-acquired pneumonia (CAP). We compared the efficacy and safety of 5 and 7 day courses of gemifloxacin for outpatient treatment of mild–moderate CAP. In a multicentre, double-blind, parallel group study, patients were randomized to receive 320 mg of oral gemifloxacin once daily for 5 or 7 days. Over 95% of all patients in each cohort had a Fine score of ≤III. The primary efficacy endpoint was clinical cure at follow-up (days 24–30). Secondary outcomes were clinical and bacteriological responses at the end of therapy (days 7–9) and bacteriological and radiological responses at follow-up. Adverse events (AEs) were also monitored. In a total of 469 per protocol (PP) patients, clinical resolution at follow-up was 95% and 92% for 5 and 7 day treatments, respectively [95% confidence interval (CI) −1.48, 7.42], indicating non-inferiority of 5 day treatment. Clinical resolution at the end of therapy was 96% for both regimens (95% CI −3.85, 3.42). Bacteriological response rates in PP patients at the end of therapy were 94% and 96% for 5 and 7 day groups, respectively (95% CI −8.27, 3.25) and 91% for both groups at follow-up (95% CI –6.89, 7.93). Radiological success in PP patients at follow-up was 98% and 93% in 5 and 7 day groups, respectively (95% CI 0.35, 7.91). Pre-therapy pathogens were identified in 242 (47.3%) patients, most commonly Streptococcus pneumoniae. Frequency of treatment-related AEs was 21% in both cohorts with discontinuation rates of 1.2% and 2% in the 5 and 7 day groups, respectively. A lower incidence of rash was observed in the 5 day cohort (0.4%) versus the 7 day cohort (2.8%) (P = 0.04). Gemifloxacin once daily for 5 days is not inferior to 7 days in the PP population with respect to clinical, bacteriological and radiological efficacy. Further work is needed, however, to explore whether fewer treatment days would improve patient compliance and reduce the incidence of AEs.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
Uranga, A., España, P. P., Bilbao, A., Quintana, J. M., Arriaga, I., Intxausti, M., Lobo, J. L., Tomás, L., Camino, J., Nuñez, J., et al. (2016) · JAMA Internal Medicine · doi:10.1001/jamainternmed.2016.3633 · Cited by 290
Vaughn, V. M., Flanders, S. A., Snyder, A., Conlon, A., Rogers, M. A. M., Malani, A. N., McLaughlin, E., Bloemers, S., Srinivasan, A., Nagel, J., et al. (2019) · Annals of Internal Medicine · doi:10.7326/m18-3640 · Cited by 247
“Patients with CAP were expected to have a treatment duration of at least 5 days, with longer courses expected only if time to clinical stability was longer (4, 21, 24).”
Duration of antibiotic therapy for bacteremia: a systematic review and meta-analysis
Havey, T. C., Fowler, R. A., & Daneman, N. (2011) · Critical Care · doi:10.1186/cc10545 · Cited by 187
Short- versus Long-Course Antibacterial Therapy for Community-Acquired Pneumonia: A Meta-Analysis
Dimopoulos, G., Matthaiou, D. K., Karageorgopoulos, D. E., Grammatikos, A. P., Athanassa, Z., & Falagas, M. E. (2008) · Drugs · doi:10.2165/00003495-200868130-00004 · Cited by 160
Falagas, M. E., Karagiannis, A. K. A., Nakouti, T., & Tansarli, G. S. (2015) · PLOS ONE · doi:10.1371/journal.pone.0116207 · Cited by 48
Furlan, L., Erba, L., Trombetta, L., Sacco, R., Colombo, G., Casazza, G., Solbiati, M., Montano, N., Marta, C., Sbrojavacca, R., et al. (2019) · Internal and Emergency Medicine · doi:10.1007/s11739-018-1955-2 · Cited by 9
Metadata
- Authors
- File, T. M., Mandell, L. A., Tillotson, G., Kostov, K., & Georgiev, O.
- Venue
- Journal of Antimicrobial Chemotherapy
- Publisher
- Oxford University Press (OUP)
- Published
- 2007-05-30
- Volume
- 60
- Issue
- 1
- Pages
- 112-120
- ISSN
- 0305-7453 (ISSN-L)
- 1460-2091
- OpenAlex
- W2119100503
- Cited by
- 68
- References
- 0
- FWCI
- 3.35
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.